In the North America, cervical cancer screening is a public health success; it is the fourth most frequent cancer prevailing in women over 30 years. It affects the lower part of the uterus (womb). Cervical cancer is a malignancy of cervical cells and is mostly caused by the Human papillomavirus (HPV) virus. In 2020, as per the American Cancer Society, around 13,800 new cases of invasive cervical cancer were being diagnosed, and about 4,290 women died from cervical cancer in the United States.


Notwithstanding, increasing awareness among the general population regarding the prevention, care, and treatment of cervical cancer, rise in certain behaviors, such as smoking, certain genetic factors, and weak immune system are all linked to the growth of the United States and Canada cervical cancer screening market. The rising number of cervical cancer cases has fueled the demand for screening programs. According to Renub Research report, United States and Canada Cervical Cancer Screening Market will reach US$ 8.2 Billion by 2027.


COVID-19 Impacts on the United States and Canada Cervical Cancer Screening Industry

The sudden outbreak of the COVID-19 pandemic had led to the implementation of stringent lockdown regulations across the United States and Canada, resulting in disruptions of Cervical Cancer Screening. Cervical cancer screening declined to meagre numbers in US and Canada due to the coronavirus pandemic. Most non-urgent cervical cancer appointments have been cancelled in the wake of COVID-19.


United States and Canada Cervical Cancer Screening Market Size was US$ 8 Billion in 2021

Besides, the growing number of cervical cancer cases surge the demand for HPV testing and PAP tests in the United States and Canada. Pap test is approved for all women between the ages of 21 to 65 every three years, and women between 30-65 are recommended to have both Pap and HPV tests. Pap test or smear test is a method that doctors use to find cell changes or abnormal cells in the cervix. Pap tests are the most preferred tests in the United States and Canada to detect cervical cancer.


Furthermore, Human papillomavirus (HPV) is the most common sexually transmitted disease (STD) in the United States. HPV tests are DNA-based and allow the detection of specific strains of the virus in the specimen. HPV tests during primary screening help in the detection of abnormal cells that become cancerous. This helps in early disease prevention, providing healthcare professionals to opt for various treatment and preventive options. United States and Canada Cervical Cancer Screening Industry is expected to grow with a CAGR of 0.41% from 2021 to 2027.


Renub Research latest report “United States and Canada Cervical Cancer Screening Market by United States – Cervical Cancer Test Analysis (Population – Cervical Cancer Test (Screening), Pap smear Test Population, HPV DNA Test Population) by United States – Cervical Cancer Test Market (Pap Smear Test Market ,HPV DNA Test Market) Canada – Cervical Cancer Test Analysis (Population – Cervical Cancer Test (Screening), Pap Smear Test Population, HPV DNA Test Population) Market – Cervical Cancer Test (Screening) (Pap Smear Test Market, HPV DNA Test Market)” provides a detailed analysis of United States and Canada Cervical Cancer Screening Industry.


United States – Cervical Cancer Test Analysis has been covered from 3 viewpoints

1. Population – Cervical Cancer Test (Screening)
2. Pap smear Test Population
3. HPV DNA Test Population


United States Cervical Cancer Mortality

Market – Cervical Cancer Test (Screening) has been covered from 2 viewpoints

1. Pap Smear Test Market
2. HPV DNA Test Market


Canada – Cervical Cancer Test Analysis has been covered from 3 viewpoints

1. Population – Cervical Cancer Test (Screening)
2. Pap Smear Test Population
3. HPV DNA Test Population


Canada Cervical Cancer Mortality

Market – Cervical Cancer Test (Screening) has been covered from 2 viewpoints

1. Pap Smear Test Market
2. HPV DNA Test Market